Factors such as the growing incidence of urolithiasis and technological advancements in lithotripsy devices are driving the growth of this market.
The report Lithotripsy Devices Market is expected to reach USD 1.76 Billion by 2023 from USD 1.41 Billion in 2018, at a CAGR of 4.5%. Ask for PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=29769904 Market Segmentation:- By type, the lithotripsy devices market is classified into extracorporeal shock wave lithotripsy devices and intracorporeal lithotripsy devices. In 2017, the extracorporeal shock wave lithotripsy devices segment accounted for the largest share of the market. ESWL is the least invasive of all stone treatments and is considered the treatment modality of choice for a majority of urinary stones. On the basis of applications, the lithotripsy devices market is categorized into kidney stones, ureteral stones, pancreatic stones, and bile duct stones. In 2017, the kidney stones segment accounted for the largest share of the market. The increasing incidence of kidney stones and the recurrence of these stones over a period of time are the key factors driving the growth of this segment. On the basis of end user, the lithotripsy devices market is categorized into hospitals, ambulatory surgical centers, and other end users. In 2017, the hospitals segment accounted for the largest share of the global lithotripsy devices market. Target Audience for this Report:-
Regional Analysis:- Based on region, the lithotripsy devices market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America dominated the lithotripsy devices market in 2017. The large share can primarily be attributed to the high prevalence of kidney stones and the large number of surgeries performed each year. Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=29769904 Top key Players:- Some of the major players in the lithotripsy devices market are Siemens AG (Germany), Boston Scientific (US), Dornier MedTech (Germany), Olympus America (Japan), DirexGroup (Germany), and Richard Wolf (Germany).
0 Comments
Growth in the market is largely driven by the growing threat of antimicrobial resistance due to the overuse of antibiotics, rising demand for animal-derived products, growing prevalence of zoonotic diseases, rising demand for pet insurance, growing animal health expenditure, and the growing number of veterinary practitioners & their rising income levels in developed economies. The rising focus on veterinary antimicrobial susceptibility testing in emerging markets due to supportive government initiatives and awareness initiatives for antimicrobial resistance and control offer significant growth opportunities for the market players.
The Veterinary Antimicrobial Susceptibility Testing Market is expected to reach USD 135 million by 2026 from an estimated USD 100 million in 2021, at a CAGR of 6.1%. Ask For PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=50401056 Since the beginning of 2020, the majority of the countries worldwide shut down their borders and limited transportation in a bid to contain the coronavirus (COVID-19) outbreak, thus, creating impediments for international trade and transportation. The food-producing animal segment is expected to account for the largest share of the veterinary AST market Based on animal type, the veterinary antimicrobial susceptibility testing market is segmented into food-producing animals and companion animals. The food-producing animals segment accounted for the largest share of the market in 2020. The large share and high growth of this segment can be attributed to the high use of antibiotics in food-producing animals, increasing incidence of antimicrobial resistance, increasing demand for meat and dairy products, rising animal healthcare expenditure in developed countries, and the increasing incidence of disease outbreaks in food-producing animals. This segment is further categorized into cattle, pigs, poultry, and other food-producing animals. Companion animals are further segmented into dogs, cats, horses, and other companion animals. The culture media segment is expected to grow at the highest rate during the forecast period The culture media segment is expected to register the highest growth rate during the forecast period. Growth in this product segment can be attributed to the constant requirement and recurrent purchase of these products for cultivating bacterial isolates under controlled environmental laboratory conditions. The veterinary reference laboratory end-user segment is expected to account for the largest share of the veterinary AST market Based on end users, the veterinary antimicrobial susceptibility testing market is segmented into veterinary reference laboratories, veterinary research institutes and universities, and other end users. Veterinary reference laboratories accounted for the largest share of the market in 2020. The large share of this segment can be attributed to the large number of samples received for AST in reference laboratories from small and large animal practices. This segment is also expected to register the highest growth during the forecast period (2021–2026). Asia Pacific is expected to account for the highest CAGR for players operating in the veterinary AST market. The Asia Pacific region is expected to register the highest CAGR during the forecast period. Growth in pet adoption, increasing awareness about animal health, and the growing per capita animal health expenditure, especially in India and China, contribute to the growth of the APAC veterinary antimicrobial susceptibility testing market. Request for Sample Pages:- https://www.marketsandmarkets.com/requestsampleNew.asp?id=50401056 Top Key Players:- Some of the major players in the veterinary antimicrobial susceptibility testing market include Thermo Fisher Scientific Inc. (US), Becton, Dickinson and Company (US), Bruker Corporation (US), bioMérieux SA (France), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US), Neogen Corporation (US), HiMedia Laboratories (India), Mast Group Ltd. (UK), Bioguard Corporation (Taiwan), SSI Diagnostica A/S (Denmark), Condalab (Spain), FASTinov SA (Portugal), Synbiosis (UK), Hardy Diagnostics (US), and Liofilchem Srl (Italy). Growing applications of multimodal imaging systems, technological advancements in diagnostic imaging modalities, availability of funding for research, favorable reimbursement scenario, growing insurance coverage, and increasing R&D into radiotracers are some of the key factors driving the multimodal imaging market.
The report Multimodal Imaging Market is projected to reach USD 2.9 billion by 2024 from USD 2.3 billion in 2019, at a CAGR of 4.4%. Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=3358876 The PET/CT segment accounted for the largest share of the multimodal imaging market, by technology, in 2018 Based on technology, the multimodal imaging market is broadly segmented into PET/CT systems, PET/MR systems, SPECT/CT systems, OCT/Fundus Imaging systems, and other multimodal imaging systems (tri-modality systems such as SPECT/CT/PET, PET/CT + MR, and IVUS + NIRS systems, among others). The PET/CT systems segment accounted for the largest share of the multimodal imaging market in 2018. This can be attributed to the increasing demand for early and accurate cancer diagnosis, growing clinical evidence for the early detection of Alzheimer’s disease, increasing applications of PET/CT systems in cardiology, favorable reimbursement scenario, and the technological advancements in the field of PET/CT. The oncology segment registered the highest CAGR in the multimodal imaging market in 2018 On the basis of application, the multimodal imaging market is segmented into brain & neurology, cardiology, oncology, ophthalmology, and other applications. The oncology segment registered the highest CAGR in 2018. This can be attributed to the expanding use of multimodal imaging systems in oncology diagnosis, increasing demand for the early & accurate diagnosis of cancer, and growing clinical evidence on the use of multimodal imaging in the diagnosis of novel cancer types. North America accounted for the largest share of the multimodal imaging market in 2018 The multimodal imaging market is segmented into four regional segments, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest share of the multimodal imaging market owing to factors such as the increasing availability of radiotracers, technological advancements in diagnostic imaging modalities, high incidence/prevalence of diseases such as breast cancer and colorectal cancer, large number of multimodal imaging procedures performed, growing awareness about the benefits of early diagnosis of diseases, and the rapid adoption of technologically advanced imaging systems. Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=3358876 Top Key Players:- The major players operating in the multimodal imaging market are GE Healthcare (US), Siemens Healthineers (Germany), Koninklijke Philips N.V. (Netherlands), United Imaging Healthcare Co., Ltd. (China), Canon Medical Systems Corporation (Japan), Mediso Medical Imaging Kft (Hungary), Neusoft Medical Systems Co., Ltd. (China), Spectrum Dynamics Medical (Switzerland), Infraredx, Inc. (Japan), Topcon Corporation (Japan), Carl Zeiss AG (Germany), and Heidelberg Engineering (Germany). The increasing advancements in the healthcare solutions and production of innovative solutions by manufacturers in the healthcare industry, the medical image analysis software is projected to record significant growth between 2017 and 2022.
The report Medical Image Analysis Software Market is expected to reach USD 3.9 billion by 2022, registering a CAGR of 8.2%. Ask for PDF Brochure: – https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=846 Market Segmentation: - The adoption of smart technology solutions is gradually transforming the approach and treatment procedures practiced in the healthcare industry. To offer cost-effective and quick medical solutions, software developers are focusing on integrating intelligent features such as cloud-based services that provide improved practice management, allow quick access to patient data saved on mobiles & other wearable devices, and monitor quality measures. As the need for quick access to essential medical information and X-rays for analysis among doctors and surgeons persists, the adoption of integrated software solutions continues to remain high. Integrated software generated the highest revenues in the medical image analysis software market in 2017. With the increasing number of chronic cases, and the growing number of clinical trial and research studies on medical conditions, the demand for medical analysis software solutions continues to remain high in the healthcare industry. Diagnostic centers, hospitals, and research centers are increasingly adopting these software solutions to maintain patient records and analyze the outcome of various treatment procedures. Regional Analysis: - Of the various regions, North America is projected to account for the largest share of the global medical image analysis software market by 2022. A recently published report of the World Health Organization (WHO) stated that by 2020, chronic diseases would account for nearly 73% of all deaths and 60% of the global burden of disease. Moreover, the number of imaging centers is increasing in the region in tandem with the growing geriatric population and the increasing prevalence of various diseases. Request for Sample Pages: –https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=846 Top Key Players: - The increasing presence of new and established players in the medical image analysis software market is likely to intensify the competition. A few prominent market players operating in this market include AQUILAB (France), AGFA Healthcare (Belgium), Esaote S.p.A (Italy), Carestream Health, Inc. (US), and GE Healthcare (US). The major factors driving the growth of the gene expression analysis market include decreasing cost of sequencing, rising prevalence of cancer, growing application areas of genomics, and the availability of gene expression databases. The global Gene Expression Analysis Market is expected to reach USD 4.9 billion by 2023 from USD 3.2 billion in 2018, at a CAGR of 8.8%. Ask for PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=156613968 Market Segmentation: - On the basis of products and services, the global gene expression analysis market has been segmented into consumables (reagents, DNA chips), Instruments (PCR, NGS, Microarray, others), and services (gene expression profiling services, bioinformatics solutions). The consumables segment is estimated to command the largest share of the market in 2018 and is also projected to register the highest CAGR. The high growth in this segment can be attributed to the growing decreasing sequencing costs leading to increased adoption of sequencing and other gene expression analysis techniques. Based on end user, the market has been segmented into pharmaceutical and biotechnology companies, academic institutes and research centers, and other end users. The pharmaceutical and biotechnology companies’ segment is expected to command the largest share of 54.8% of the market in 2018. The large share and high growth of this segment can be attributed to factors such as high volume of research studies involving gene expression analysis and huge capital for high end analysis instruments and consumables. Regional Analysis: - Geographically, North America is expected to dominate the global gene expression analysis market in 2018, while the Asia Pacific region is expected to register the highest CAGR during the forecast period. The high growth in this region can be attributed to domestic manufacturing of sequencing systems, western partnerships to improve healthcare, high R&D intensity, government focus on cancer and other life science research, and flourishing bioresearch centers. Request for Sample Pages:-https://www.marketsandmarkets.com/requestsampleNew.asp?id=156613968 Top Key Players:- The major players operating in the gene expression analysis market include Illumina, Inc. (US), Thermo Fisher Scientific, Inc. (US), and Bio-Rad Laboratories, Inc. (US) are the key players in the gene expression analysis market. Other players involved in this market are F. Hoffmann-La Roche Ltd. (Switzerland), GE Healthcare (UK), Pacific Biosciences of California, Inc. (US), BGI (China), PerkinElmer (US), Agilent Technologies Inc. (US), and QIAGEN N. V. (Netherlands), among others. The growth of this market can be attributed to the rising preference for continuous manufacturing in the biopharmaceutical industry and the increasing demand for biopharmaceuticals across the globe.
The report Hollow Fiber Filtration Market is projected to reach USD 517.4 million by 2023 from USD 274.7 million in 2018, growing at a CAGR of 13.5%. Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=267011039 Market Segmentation:- On the basis of application, the hollow fiber filtration market is segmented into continuous cell perfusion, harvest and clarification, and concentration and diafiltration. In 2018, continuous cell perfusion is expected to be the largest application segment in the hollow fiber filtration market. The biopharmaceutical industry is actively exploring the potential of continuous manufacturing, with a focus on upstream perfusion cell-culture processes that utilize hollow fiber filters. Due to the advantages of hollow fibers, such as achieving efficient cell separation (with low shear) and allowing robust large-scale manufacturing, they are considered as the most suitable form of membrane filters for TFF and ATF perfusion processes. On the basis of material, the Hollow Fiber Filtration Industry is segmented into polymeric and ceramic materials. In 2018, the polymeric hollow fiber filtration segment is expected to account for a larger share of the market as these filters are widely used in several ultrafiltration and microfiltration applications, including filtration, desalination, and biochemical reactions. Key Market Drivers: - 1 Rising Preference for Continuous Manufacturing 2 Increasing Demand for Biopharmaceuticals Regional Analysis:- The Asian Pacific is expected to be the fastest-growing regional market for hollow fiber filtration. The high growth in this regional market can be attributed to the expansion of the biomanufacturing sector, increasing government support, developing R&D infrastructure, and growing outsourcing of bioproduction processes to Asia Pacific countries such as China and India. Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=267011039 Top Key Players:- The Hollow Fiber Filtration Industry is consolidated due to the presence of a few major players. Asahi Kasei Corporation (Japan), Repligen Corporation (US), GE Healthcare (US), Danaher Corporation (US), and Koch Membrane Systems (US) are the leading players in this market. Factors such as the growing awareness related to the therapeutic potency of stem cells in disease management, development of advanced genome-based cell analysis techniques, increasing public-private investments for stem cell research, identification of new stem cell lines, and developments in infrastructure for stem cell banking and processing are propelling the growth of the global stem cell therapy market.
The Stem Cell Therapy Market is expected to reach USD 161.8 million by 2022, growing at a CAGR of 11.0% during the forecast period. Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=48 Market Segmentation: - On the basis of mode of therapy, the global stem cell therapy market is divided into two major categories, namely, allogeneic stem cell therapy and autologous stem cell therapy. The allogeneic stem cell therapy segment is expected to command the largest share of 95.2% in the global stem cell therapy market in 2017 growing at a CAGR of 11.2% during the forecast period. On the basis of therapeutic application, the global Stem Cell Therapy Industry is segmented into musculoskeletal disorders, wounds and injuries, cardiovascular diseases, surgeries, gastrointestinal diseases, and other applications. The musculoskeletal disorders segment is expected to command the largest share of 61.1% in the global stem cell therapy market in 2017. Furthermore, the CVS diseases segment is expected to grow at the highest CAGR of 13.0% during the forecast period. On the basis of cell source, the global Stem Cell Therapy Industry is divided into adipose derived MSCs, bone marrow derived MSCs, embryonic / cord blood SCs, and other cell sources. The adipose derived MSCs segment was expected to account for the largest share of 59.1% in the global stem cell therapy market in 2017. Market Growth Drivers :- 1 Growing Awareness Related to the Therapeutic Potency of Stem Cells in Effective Disease Management 2 Development of Advanced Genome-Based Cell Analysis Techniques 3 Increasing Public-Private Investments for the Development of Stem Cell Therapies 4 Development in Infrastructure Related to Stem Cell Banking and Processing Regional Analysis:- North America is expected to be the largest regional segment in the global stem cell therapy market in 2017, followed by Asia-Pacific. In addition, the North American stem cell therapy market is expected to be the fastest growing region during the forecast period, growing at a CAGR of 11.5%. Request for Sample Pages :-https://www.marketsandmarkets.com/requestsampleNew.asp?id=48 Key Market Players:- As of 2016, Osiris Therapeutics, Inc. (U.S.), MEDIPOST Co., Ltd. (South Korea), Anterogen Co., Ltd. (South Korea), Pharmicell Co., Ltd. (South Korea), Holostem Terapie Avanzate S.r.l. (Italy), JCR Pharmaceuticals Co., Ltd. (Japan), NuVasive, Inc. (U.S.), RTI Surgical, Inc. (U.S.), and AlloSource (U.S.) were some of the key players operating in the global stem cell therapy market. Factors like growing need for effective and early diagnosis, rising global prevalence of targeted, increasing preference for minimally invasive diagnostic procedures, increasing benefits of CT scans, and technological advancements are driving the growth of the market.
The Global CT Scanner Market is projected to reach USD 6.20 Billion by 2022, at a CAGR of 5.4% during the forecast period. Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=184364345 Cone beam CT technology segment poised to grow fastest in CT scanner market. On the basis of technology, the CT scanners market is segmented into high-slice CT, mid-slice CT, low-slice CT, and cone beam CT technology. The cone beam CT technology segment is expected to grow faster than the other segments during the forecast period, majorly due to factors like procedural advantages; rising market demand for cosmetic dentistry; and ongoing product development & commercialization across major healthcare markets. Portable CT scanners segment expected to register fastest growth rate in the forecast period. Based on type, the CT scanners market is divided into stationary and portable CT scanners. Portable CT scanners segment is poised to grow faster than the other segment due to increasing number of device installations across major markets, growing application horizons, and the lower switching costs provided by portable CT scanners. North America accounted for the largest share of the CT scanner market Geographically, the CT scanner market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America accounted for the largest share of the market in 2017, which is primarily driven by growth in the aging U.S. population; an increasing public emphasis on minimally invasive & effective disease management strategies; robust reimbursement scenario; increasing adoption of novel applications; and rising public-private investments. Request for Sample Pages:- https://www.marketsandmarkets.com/requestsampleNew.asp?id=184364345 The major players in the CT scanner market are Koninklijke Philips N.V. (Netherlands), GE Healthcare (U.S.), Toshiba Corporation (Japan), Siemens AG (Germany), Hitachi Ltd. (Japan), Shimadzu Corporation (Japan), Samsung Electronics Co., Ltd. (South Korea), Neusoft Medical Systems Co., Ltd. (China), Medtronic plc (Ireland), Shenzhen Anke High-tech Co., Ltd. (Hong Kong), Accuray Incorporated (U.S.), PlanMED (Finland), Koning Corporation (U.S.), Carestream Health Inc. (U.S.), and PointNix Co. Ltd (South Korea). The key factors driving the growth of this market are the growing prevalence of chronic diseases (such as cancer, diabetes, and cardiovascular diseases), favorable reimbursement scenario in major markets, and technological advancements in injector devices.
The Wearable Injectors Market is projected to reach USD 9.41 billion by 2023 from USD 5.57 billion in 2018, at a CAGR of 11.1% during the forecast period. Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=100771004 Market Segmentation:- On the basis of type, the Wearable Injectors Industry is segmented into on-body and off-body injectors. The on-body injectors segment is expected to account for the larger market share in 2018, while the off-body injectors segment is projected to witness the highest growth rate during the forecast period. The drawbacks associated with on-body wearable injectors, such as painful removal, skin sensitivity issues and irritation, and adhesive fitting issues have resulted in the increased adoption of off-body injectors. On the basis of therapy, the wearable injectors market is segmented into immuno-oncology, diabetes, cardiovascular diseases, and other therapies (Parkinson’s disease, thalassemia, and primary immunodeficiency disorders). In 2018, the immune-oncology segment is expected to account for the largest share of the wearable injectors market. This can be attributed to the high prevalence of cancer across the globe. Recent Developments:-
In 2018, North America is expected to account for the largest share of the wearable injectors market, followed by Europe. Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=100771004 Top Key Players: - The key players in the global Wearable Injectors Industry are Amgen (US), Medtronic (Ireland), Insulet Corporation (US), Tandem Diabetes Care (US), United Therapeutics Corporation (US), Valeritas (US), and SteadyMed Therapeutics (US). The other prominent players in this market are Ypsomed (Switzerland), Becton, Dickinson and Company (US), Enable Injections (US), Sensile Medicals (Switzerland), and Bespak (UK). High prevalence of ophthalmic disorders, rapid growth in geriatric population, technological advancements, increasing regulatory approvals for ophthalmic lasers, rising prevalence of chronic diseases such as diabetes, and increasing initiatives to control visual impairment are expected to drive the growth of the global ophthalmic lasers market in the coming years.
The Ophthalmic Lasers Market is expected to reach USD 1,245.4 Million by 2021 from USD 970.2 Million in 2016, at a CAGR of 5.1% from 2016 to 2021. Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=251971654 Market Segmentation:- The global ophthalmic lasers market is segmented on the basis of product types, applications, end users, and regions. Based on product type, the ophthalmic lasers market is categorized into femtosecond lasers, excimer lasers, Nd:YAG lasers, diode lasers, and others. The femtosecond lasers segment is expected to command the largest share of the global ophthalmic lasers market, by product type and is projected to grow at the highest CAGR during the forecast period. Based on applications, the ophthalmology lasers market is segmented into refractive error correction, cataract removal, glaucoma treatment, diabetic retinopathy treatment, AMD treatment, and other applications. In 2016, the refractive error correction segment is expected to command the largest share of the global ophthalmic lasers market. Based on end users, the ophthalmic lasers market is segmented into hospitals and clinics & ambulatory surgery centers (ASCs). The hospitals segment is projected to command the largest share of the global ophthalmic lasers market. Key Market Drivers:- 1 High Prevalence of Ophthalmic Disorders 2 Rapid Growth in Geriatric Population 3 Technological Advancements and Increasing Regulatory Approvals for Ophthalmic Lasers 4 Rising Prevalence of Chronic Diseases Such as Diabetes 5 Increasing Initiatives to Control Visual Impairment Regional Analysis:- Based on regions, the ophthalmology lasers market is divided into North America, Europe, Asia-Pacific, and the Rest of the World. In 2016, North America is expected to account for the largest share of the global ophthalmic lasers market. Request for Sample Pages:- https://www.marketsandmarkets.com/requestsampleNew.asp?id=251971654 Key Market Players:- Alcon Laboratories, Inc. (U.S.), Abbott Medical Optics, Inc. (U.S.), Carl Zeiss Meditec AG (Germany), Bausch & Lomb Incorporated (U.S.), Ellex Medical Lasers Limited (Australia), Topcon Corporation (Japan), Ziemer Ophthalmic Systems AG (Switzerland), IRIDEX Corporation (U.S.), NIDEK Co., Ltd. (Japan), and Lumenis Ltd. (Israel) are some of the key players in the ophthalmic lasers market. |
AuthorWe are providing and consulting the healthcare Industry Research Report. Archives
March 2022
Categories |